| Raushan Abdula, MD | |
|
1201 Sam Perry Blvd # B, Suite 205, Fredericksburg, VA 22401-4490 | |
| (855) 739-9953 | |
| (888) 463-3944 |
| Full Name | Raushan Abdula |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 37 Years |
| Location | 1201 Sam Perry Blvd # B, Fredericksburg, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720206212 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 0101250434 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Washington Hospital | Fredericksburg, VA | Hospital |
| Stafford Hospital, Llc | Stafford, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mary Washington Healthcare Physicians | 2769546530 | 285 |
| Oracle Heart And Vascular Inc | 5890926075 | 14 |
News Archive
The Health Protection Agency has this week issued symptom-based clinical action cards to all GPs in England to help them recognise unusual symptoms. The cards do not reflect any increased threat to the public, but have been developed in response to requests from the medical profession for more specific training in the recognition of unusual symptoms caused by emerging diseases and by chemical, biological, radiological and nuclear (CBRN) hazards.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.
Mylan Inc. has announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has received the first tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg.
Declining kidney function is linked to a higher risk of heart failure, heart attack, peripheral arterial disease, and early death in individuals with or without kidney disease, according to a pair of studies appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).
› Verified 3 days ago
| Entity Name | Mary Washington Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013089879 PECOS PAC ID: 0446143820 Enrollment ID: O20040209000155 |
News Archive
The Health Protection Agency has this week issued symptom-based clinical action cards to all GPs in England to help them recognise unusual symptoms. The cards do not reflect any increased threat to the public, but have been developed in response to requests from the medical profession for more specific training in the recognition of unusual symptoms caused by emerging diseases and by chemical, biological, radiological and nuclear (CBRN) hazards.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.
Mylan Inc. has announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has received the first tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg.
Declining kidney function is linked to a higher risk of heart failure, heart attack, peripheral arterial disease, and early death in individuals with or without kidney disease, according to a pair of studies appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).
› Verified 3 days ago
| Entity Name | Mary Washington Healthcare Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295999852 PECOS PAC ID: 2769546530 Enrollment ID: O20090123000298 |
News Archive
The Health Protection Agency has this week issued symptom-based clinical action cards to all GPs in England to help them recognise unusual symptoms. The cards do not reflect any increased threat to the public, but have been developed in response to requests from the medical profession for more specific training in the recognition of unusual symptoms caused by emerging diseases and by chemical, biological, radiological and nuclear (CBRN) hazards.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.
Mylan Inc. has announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has received the first tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg.
Declining kidney function is linked to a higher risk of heart failure, heart attack, peripheral arterial disease, and early death in individuals with or without kidney disease, according to a pair of studies appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).
› Verified 3 days ago
| Entity Name | Stafford Hospital, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750714440 PECOS PAC ID: 3779650262 Enrollment ID: O20131101000347 |
News Archive
The Health Protection Agency has this week issued symptom-based clinical action cards to all GPs in England to help them recognise unusual symptoms. The cards do not reflect any increased threat to the public, but have been developed in response to requests from the medical profession for more specific training in the recognition of unusual symptoms caused by emerging diseases and by chemical, biological, radiological and nuclear (CBRN) hazards.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.
Mylan Inc. has announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has received the first tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg.
Declining kidney function is linked to a higher risk of heart failure, heart attack, peripheral arterial disease, and early death in individuals with or without kidney disease, according to a pair of studies appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).
› Verified 3 days ago
| Entity Name | Oracle Heart & Vascular Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972924520 PECOS PAC ID: 5890926075 Enrollment ID: O20140401002287 |
News Archive
The Health Protection Agency has this week issued symptom-based clinical action cards to all GPs in England to help them recognise unusual symptoms. The cards do not reflect any increased threat to the public, but have been developed in response to requests from the medical profession for more specific training in the recognition of unusual symptoms caused by emerging diseases and by chemical, biological, radiological and nuclear (CBRN) hazards.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.
Mylan Inc. has announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has received the first tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg.
Declining kidney function is linked to a higher risk of heart failure, heart attack, peripheral arterial disease, and early death in individuals with or without kidney disease, according to a pair of studies appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Raushan Abdula, MD Po Box 3339, Fredericksburg, VA 22402-3339 Ph: (855) 739-9953 | Raushan Abdula, MD 1201 Sam Perry Blvd # B, Suite 205, Fredericksburg, VA 22401-4490 Ph: (855) 739-9953 |
News Archive
The Health Protection Agency has this week issued symptom-based clinical action cards to all GPs in England to help them recognise unusual symptoms. The cards do not reflect any increased threat to the public, but have been developed in response to requests from the medical profession for more specific training in the recognition of unusual symptoms caused by emerging diseases and by chemical, biological, radiological and nuclear (CBRN) hazards.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.
Mylan Inc. has announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has received the first tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg.
Declining kidney function is linked to a higher risk of heart failure, heart attack, peripheral arterial disease, and early death in individuals with or without kidney disease, according to a pair of studies appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).
› Verified 3 days ago
Dr. Thomas P Officer, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 101 Park Hill Dr, Fredericksburg, VA 22401 Phone: 540-371-3010 Fax: 540-899-9821 | |
Mrs. Jennifer Lynn Ross, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4510 Plank Rd Ste 200, Fredericksburg, VA 22407 Phone: 540-870-6550 Fax: 540-870-6552 | |
Dr. Robert H Seamon, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 130 Executive Center Pkwy, Fredericksburg, VA 22401 Phone: 540-370-4468 Fax: 540-370-4460 | |
Anson Le Pham, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2300 Fall Hill Ave Ste 401, Fredericksburg, VA 22401 Phone: 540-741-3580 | |
Harry Garrett Oldland, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 4535 Spotsylvania Pkwy, Fredericksburg, VA 22408 Phone: 540-374-3160 | |
Dien Nguyen, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 3031 Plank Rd, Fredericksburg, VA 22401 Phone: 540-736-5043 Fax: 540-736-5044 | |
Shahab S Virani, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1300 Thornton St Ste 200, Fredericksburg, VA 22401 Phone: 540-371-6810 Fax: 540-371-9154 |